---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-025983"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:51:41.095757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Movano Q1 net loss $6.9M; validates SoC for glucose, BP; beta on track for 2H 2022

## Summary
- Net loss of $6.9M ($0.21/share) vs $8.1M ($1.01/share) in Q1 2021; operating loss $6.9M.
- Cash and investments $27.7M as of Mar 31, 2022, down from $33.6M at Dec 31, 2021.
- Validated proprietary mmWave SoC for non-invasive glucose and cuffless blood pressure monitoring.
- Hired go-to-market leadership team; added Nan Kirsten Forte to Board; plans limited beta release in 2H 2022.
- No revenue generated; company remains development stage with R&D focus.

## SEC filing metadata
- accession: 0001213900-22-025983
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390022025983/0001213900-22-025983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390022025983/ea159721-8k_movano.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-025983
- JSON: https://secwatch.observer/filing/0001213900-22-025983.json
- Plain text: https://secwatch.observer/filing/0001213900-22-025983.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.